Empasiprubart

Empasiprubart (formerly ARGX-117) is designed to be a humanized sweeping antibody that binds specifically to C2 in a pH- and Ca2+- dependent manner. C2 is a protein in the complement cascade which, when activated, leads to cell destruction. Binding of Empasiprubart is intended to inhibit the function of C2 and downstream complement activation.

By blocking complement activity, Empasiprubart has the potential to reduce tissue inflammation and the adaptive immune response. Through this proposed mechanism, Empasiprubart could represent a broad pipeline opportunity across severe autoimmune indications.

Neurology
Hematology / Rheumatology
Dermatology
Nephrology
Indication not disclosed
Program
Clinical trial

Pipeline

Empasiprubart

Target
C2
Preclinical
Phase 1
Proof of Concept
Registrational
Commercial
Multifocal Motor Neuropathy (MMN)
  • ARGX-117 is designed to block complement activity with potential to reduce tissue inflammation and the adaptive immune response
  • IV ARGX-117 and SC ARGX-117 (enabled with Halozyme's ENHANZE® drug delivery technology)
Delayed Graft Function (DGF)
Dermatomyositis (DM)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
  • CIDP is a rare, chronic disorder where damage to peripheral nerves, which may be caused by antibodies, results in progressive weakness and a loss of feeling in the arms and legs
  • SC efgartigimod